Assessing the risk of adverse drug events from combining aromatase inhibitors with CDK4/6 inhibitors using the FAERS and JADER databases

• by Zhipeng Fan, Peikai Sun, Lei Li

• July 6, 2026

Management challenges in metachronous bilateral breast cancer with discordant receptor status: a case report

• by Aime Ishimwe Mugisha, Gilbert Denis Umuhizi, Gerald Olwit

• June 26, 2026

Isoflavones impair anti-PD1 efficacy in breast cancer, regardless of dietary fiber or fecal short-chain fatty acid levels

• by Fabia de Oliveira Andrade, Kerrie B. Bouker, Melike Ozgul-Onal, Lu Jin, Idalia Cruz, William Helferich, Audrey Gao, Karla Andrade de Oliveira, Vivek Verma, Christopher Staley, Patricia L. Foley, Leena Hilakivi-Clarke

• July 6, 2026

ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.

• July 1, 2026

• 1 min